[go: up one dir, main page]

MX9708663A - Inhibidor de actividad il-6. - Google Patents

Inhibidor de actividad il-6.

Info

Publication number
MX9708663A
MX9708663A MX9708663A MX9708663A MX9708663A MX 9708663 A MX9708663 A MX 9708663A MX 9708663 A MX9708663 A MX 9708663A MX 9708663 A MX9708663 A MX 9708663A MX 9708663 A MX9708663 A MX 9708663A
Authority
MX
Mexico
Prior art keywords
nucleotide sequence
absent
relates
activity inhibitor
activity
Prior art date
Application number
MX9708663A
Other languages
English (en)
Other versions
MXPA97008663A (es
Inventor
Ottaviano Serlupi-Crescenzi
Annarita Pezzotti
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA97008663A publication Critical patent/MXPA97008663A/es
Publication of MX9708663A publication Critical patent/MX9708663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a una secuencia de nucleotido la cual es capaz de inhibir la actividad Il/6 su uso en terapia, así como composiciones farmacéuticos que la contiene. En particular, se refiere a una secuencia de nucleotido que comprende: i) por lo menos una secuencia de nucleotido que es un elemento APRE de la formula general ZXMYKGKAA, en donde Z representa T o G o también puede estar ausente, X representa T o también puede estar ausente, M representa C o A, Y representa C o T y K representa T o G, junto con ii) por lo menos una secuencia de nucleotido que constituye un sitio de union de factor de transcripcion diferente al elemento de APRE, tales como aquellos presentes en las regiones promotoras.
MX9708663A 1995-05-11 1995-05-11 Inhibidor de actividad il-6. MX9708663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/001778 WO1996035782A1 (en) 1995-05-11 1995-05-11 Il-6 activity inhibitor

Publications (2)

Publication Number Publication Date
MXPA97008663A MXPA97008663A (es) 1998-02-01
MX9708663A true MX9708663A (es) 1998-02-28

Family

ID=8166014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708663A MX9708663A (es) 1995-05-11 1995-05-11 Inhibidor de actividad il-6.

Country Status (16)

Country Link
US (1) US6004813A (es)
EP (1) EP0824588B1 (es)
JP (1) JP4173539B2 (es)
KR (1) KR100449677B1 (es)
AT (1) ATE271128T1 (es)
AU (1) AU715125B2 (es)
CA (1) CA2220433C (es)
DE (1) DE69533264T2 (es)
DK (1) DK0824588T3 (es)
ES (1) ES2220929T3 (es)
IL (1) IL118158A (es)
MX (1) MX9708663A (es)
RU (1) RU2205874C2 (es)
UA (1) UA63888C2 (es)
WO (1) WO1996035782A1 (es)
ZA (1) ZA963593B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0869176A4 (en) * 1995-11-07 2000-09-20 Kaneka Corp AUTOANTIGENS
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO1999051259A2 (en) 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP0972780A1 (en) * 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
CA2343101A1 (en) * 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
WO2003054161A2 (en) 2001-12-20 2003-07-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
WO2003084937A2 (en) * 2002-04-10 2003-10-16 Orchid Chemicals & Pharmaceuticals Limited Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
JP2008533122A (ja) * 2005-03-18 2008-08-21 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規なチロシン誘導体
US20080267888A1 (en) * 2005-05-26 2008-10-30 Pandey Surendrakumar Satyanara Heterocyclic Derivatives
WO2007000655A2 (en) * 2005-06-28 2007-01-04 Orchid Research Laboratories Limited Novel pyrazolopyrimidinone derivatives
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
WO2007083182A2 (en) * 2006-01-19 2007-07-26 Orchid Research Laboratories Limited Novel heterocycles
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
DK2158316T3 (en) * 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
MX336946B (es) 2008-02-01 2016-02-08 Orchid Res Lab Ltd Heterociclos novedosos.
EP2370451B1 (en) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
ES2750689T3 (es) 2014-08-15 2020-03-26 Adynxx Inc Señuelos oligonucleotídicos para el tratamiento del dolor

Also Published As

Publication number Publication date
DE69533264D1 (de) 2004-08-19
UA63888C2 (en) 2004-02-16
JP4173539B2 (ja) 2008-10-29
IL118158A (en) 2004-07-25
ZA963593B (en) 1996-11-25
DE69533264T2 (de) 2004-11-25
EP0824588A1 (en) 1998-02-25
ES2220929T3 (es) 2004-12-16
EP0824588B1 (en) 2004-07-14
ATE271128T1 (de) 2004-07-15
US6004813A (en) 1999-12-21
KR100449677B1 (ko) 2004-11-20
RU2205874C2 (ru) 2003-06-10
WO1996035782A1 (en) 1996-11-14
AU2526795A (en) 1996-11-29
JPH11504816A (ja) 1999-05-11
DK0824588T3 (da) 2004-08-16
CA2220433A1 (en) 1996-11-14
HK1016213A1 (en) 1999-10-29
CA2220433C (en) 2010-02-16
KR19990014681A (ko) 1999-02-25
AU715125B2 (en) 2000-01-20
IL118158A0 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
MX9708663A (es) Inhibidor de actividad il-6.
DE69526790D1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
HU9601449D0 (en) Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
MY117948A (en) Nitride oxide synthase inhibitors.
YU25399A (sh) 6-fenilpiridil-2-amino derivati korisni kao nos inhibitori
RU97120584A (ru) Ингибитор активности il-6
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
MY111201A (en) New imidazopyridines
NO20092860L (no) 2, 6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE194378T1 (de) Neosäure als korrosinsinhibitoren
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
DE69816280D1 (de) Inhibitoren des impdh-enzyms
MX9303694A (es) Peptidos.
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
UA35589C2 (uk) ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
AU5155996A (en) Control of pod dehiscence
ATE332379T1 (de) Menschliche dnase resistent gegen actininhibitoren
MX9801190A (es) Inhibidores de prolil endopeptidasa.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DK1235850T3 (da) Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser